About this study
PrEP is medicine given to prevent Human Immunodeficiency Virus (HIV) infection before it occurs. Cabotegravir is a new drug that has been found to be effective at preventing HIV among adults.
HPTN 083-01 was a study to find out if long-acting, injectable cabotegravir (CAB LA) for PrEP (pre-exposure prophylaxis) is safe and acceptable to use in adolescents.
St. Jude was one of four sites participating in the study. Denver, Chicago and Boston were the other study sites. The study enrolled a total of 50 participants at all locations.
Who was eligible for the HPTN 083-01 study?
Participants were eligible for this study if:
- They were 17 years old or younger
- They did not have HIV
- They were assigned male at birth
- They had or were interested in sexual experiences with male or transgender partners
Why was the study important?
More than 20% of new HIV infections occur among young people ages 13 to 24. PrEP medicine is an effective way to prevent HIV infection in at-risk adolescents and adults.
Only two PrEP medicines are currently approved by the U.S. Food and Drug Administration. Both of these medicines are taken as pills. A long-acting, injectable form of PrEP, such as cabotegravir, could give at-risk individuals another preventive option.